Harvest Moon Pharmaceuticals USA — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Harvest Moon Pharmaceuticals USA is a private, commercial-stage company specializing in complex generics and biosimilars, with a legacy pipeline acquired from TCI Generics. It operates a development and manufacturing model aimed at out-licensing products to partners worldwide, supported by an international sales force via PanGenerika B.V. The company's strategy targets the high-value, difficult-to-manufacture segment of the generic drug market to provide lower-cost alternatives to branded biologics and complex therapeutics.

BiosimilarsGeneric Drugs

Technology Platform

Integrated development and manufacturing platform for complex generics and biosimilars, with FDA and EMA-approved facilities.

Opportunities

The global biosimilars market is expanding rapidly due to patent expiries of major biologics and government policies promoting cost savings.

The company's established regulatory-approved manufacturing and international commercial partnership provides a direct channel to capitalize on this growth in multiple markets.

Risk Factors

The company faces significant regulatory hurdles and potential patent litigation that can delay product launches.

Its out-licensing model creates dependency on partners' commercial execution, and intensifying competition in the biosimilars space could lead to rapid price erosion.

Competitive Landscape

Harvest Moon competes in the complex generics and biosimilars sector against large generic pharmaceutical companies (e.g., Teva, Viatris) and dedicated biosimilar developers (e.g., Celltrion, Samsung Bioepis). Its differentiation lies in its focused development capabilities and partnership-centric commercial model rather than direct sales scale.

More companies in Biologics / Biosimilars →More companies in United States →